Long-Acting Cabotegravir and Rilpivirine: Innovation, New Challenges, and Opportunities-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Long-Acting Cabotegravir and Rilpivirine: Innovation, New Challenges, and Opportunities

Published:2023-01-20 Issue:9 Volume:76 Page:1655-1657
ISSN:1058-4838
Container-title:Clinical Infectious Diseases
language:en
Short-container-title:

Author:

Llibre Josep M¹,Kuritzkes Daniel A R²

Affiliation:

1. Division of Infectious Diseases, University Hospital Germans Trias, and Fight Infections Foundation , Badalona, Barcelona , Spain

2. Division of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School , Boston, Massachusetts , USA

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Microbiology (medical)

Link

https://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciad024/49121529/ciad024.pdf

Reference11 articles.

1. Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression;Swindells;N Engl J Med,2020

2. Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection;Orkin;N Engl J Med,2020

3. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study;Overton;Lancet,2020

4. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection: 152-week results from ATLAS-2M, a randomized, open-label, phase 3b, noninferiority study;Overton;Clin Infec Dis,2023

5. Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor–sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1. A randomized, controlled equivalence trial;Lennox;Ann Intern Med,2014

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rilpivirine and cabotegravir trough concentrations in people with HIV on long-term treatment with long-acting injectable antiretrovirals;Journal of Antimicrobial Chemotherapy;2024-03-26

2. Letter to the Editor: Real-Life Experience of Long-Acting Cabotegravir–Rilpivirine Combination in a Person Living with HIV with Detectable Viremia: A Case Report;AIDS Research and Human Retroviruses;2024-02-02

3. Virological Failure After Switch to Long-Acting Cabotegravir and Rilpivirine Injectable Therapy: An In-depth Analysis;Clinical Infectious Diseases;2024-01-11

4. An update on long-acting agents in HIV therapy;Future Virology;2023-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3